Amarin Corporation Plc (AMRN)

NASDAQ: AMRN · IEX Real-Time Price · USD
1.92
-0.07 (-3.52%)
Jun 24, 2022 4:00 PM EDT - Market closed
-3.52%
Market Cap 762.26M
Revenue (ttm) 535.65M
Net Income (ttm) -22.21M
Shares Out 397.01M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE 500.00
Dividend n/a
Ex-Dividend Date n/a
Volume 2,669,441
Open 2.01
Previous Close 1.99
Day's Range 1.90 - 2.01
52-Week Range 1.11 - 5.97
Beta 2.12
Analysts Buy
Price Target 3.64 (+89.6%)
Earnings Date Aug 4, 2022

About AMRN

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Moc... [Read more...]

Industry Biotechnology
IPO Date Apr 1, 1993
CEO Joseph Zakrzewski
Employees 560
Stock Exchange NASDAQ
Ticker Symbol AMRN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for AMRN stock is "Buy." The 12-month stock price forecast is 3.64, which is an increase of 89.58% from the latest price.

Price Target
$3.64
(89.58% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Sarissa Capital Intends to Vote “Abstain” at the Amarin Annual Meeting

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN) regarding how it intends to vote at the upcoming ...

Amarin Receives Positive Recommendation from United Kingdom's (UK) National Institute for Health and Care Excellence ...

UK's NICE issued its draft Final Appraisal Document (FAD) recommending the use of VAZKEPA® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated...

Penny Stocks To Buy Now? 4 To Watch With Big News

Penny stocks to watch The post Penny Stocks To Buy Now? 4 To Watch With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: CLVSMULNQNRX

Amarin stock surges after plan to cut total workforce by 40%

Shares of Amarin Corp. AMRN, hiked up 5.4% in premarket trading Monday, after the drug maker said it would reduce its workforce by 40% as part of its plan to cut operating costs by $100 million over the...

Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. Business

-- Company Expects to Achieve Approximately $100 Million in Cost Savings Over the Next 12 Months* While Continuing to Invest in European Launches and Global Expansion -- -- Reduces U.S. Commercial Organ...

Amarin Appoints Tom Reilly as New Chief Financial Officer

-- Experienced Executive Brings More Than Twenty Years of Global Financial Leadership to Amarin -- -- Michael W. Kalb to Depart Amarin to Pursue Other Interests --

Why Amarin Stock Blasted Higher on Friday

An activist investor is getting more active with the company.

4 Hot Penny Stocks With News To Watch Right Now

Hot penny stocks to watch. The post 4 Hot Penny Stocks With News To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: APLTSOPAXELA

Why Shares of Amarin Corporation Dropped 46.1% in May

The biopharmaceutical company's lowered revenue is scaring off investors.

Amarin Announces Appointment of New Directors and Board Leadership Changes

Erin Enright and Alfonso “Chito” Zulueta Appointed to Board of Directors

Research Presented at the American Heart Association's Quality of Care and Outcomes Research (QCOR) Scientific Sessio...

DUBLIN, Ireland and BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that research on the potential population health impact and cost-effectivenes...

New Strong Sell Stocks for May 13th

DDD, AMRN, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2022.

Other symbols: BDXDDD

Amarin to Present at Two Upcoming Investor Conferences

DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin's president and chief executive officer, will pres...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amarin Corporation plc - AMRN

New York, New York--(Newsfile Corp. - May 9, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Amarin Corporation plc ("Amarin" or the "Company") (NASDAQ: AMRN). Such investors are...

Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics

Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and COVID-related disruptions during the first quarter. The company's stock falls significantly on May 4.

Why Amarin Stock Is Sinking on Wednesday

Missed expectations on the top and bottom lines suggest Amarin's path forward isn't as clear as investors want it to be.

Why Amarin Shares Are Plunging After Q1 Earnings

Amarin Corporation plc (NASDAQ: AMRN) shares are plunging after it said it would continue suspending 2022 revenue guidance and Q1 earnings came short of expectations. The update follows the ongoing glob...

Amarin Reports First Quarter 2022 Financial Results and Provides Business Update

Initiated Next Phase of European Expansion Strategy with First National Reimbursement in Sweden

New Analysis Reveals Icosapent Ethyl Significantly Reduces Risk of Major Cardiovascular Events in Patients with Prior...

The latest prespecified and post hoc sub-analysis of the landmark REDUCE-IT ® study, published today in the Journal of the American College of Cardiology (JACC), demonstrated that VASCEPA ® (icosapent e...

Amarin Partner HLS Therapeutics Completes Reimbursement Negotiations with Pan-Canadian Pharmaceutical Alliance (pCPA)...

DUBLIN, Ireland and BRIDGEWATER, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today its partner HLS Therapeutics has completed negotiations with Canada's pan-C...

Amarin to Report First Quarter 2022 Financial Results and Host Conference Call On May 4, 2022

DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin's senior managem...

Eicosapentaenoic Acid (EPA) Combined with Widely Used Statins Significantly Reduced Lipid Oxidation in Model Membranes

Experimental trial research presented at the American College of Cardiology's 71st Annual Scientific Session showed that the combinations of EPA/atorvastatin active metabolite (ATM) and of EPA/rosuvasta...

Amarin Receives Reimbursement for VAZKEPA® in Sweden

Marks First Health Technology Assessment (HTA) Reimbursement in Europe and Initiation of Next Phase of the Company's Growth Strategy

Latest Research Evaluating VASCEPA® (Icosapent Ethyl) to be Presented at the American College of Cardiology's 71st An...

Amarin-Supported Research and Analyses to Be Featured in Six Presentations Amarin-Supported Research and Analyses to Be Featured in Six Presentations

Latest analysis shows VASCEPA® (icosapent ethyl) significantly lowered the risk of potentially fatal cardiovascular e...

A new post hoc sub-analysis of the landmark REDUCE-IT Study, published in the Journal of the American Heart Association (JAHA), found VASCEPA® significantly reduced the risk of cardiovascular death, str...